Barriers to the use of prandial insulin regimens include inadequate synchronization of insulin action to postprandial plasma glucose excursions as well as a significant risk of hypoglycemia and weight gain. Technosphere® insulin (TI) is an inhaled ultra-rapid-acting human insulin that is quickly absorbed in the alveoli. With a time to maximum plasma drug concentration of approximately 14 min and a time to maximum effect of 35 to 40 min, TI more closely matches the postprandial insulin concentrations seen in nondiabetic individuals. Studies have shown that long-term administration of prandial TI in combination with long-acting basal insulin results in reductions in hemoglobin A1c comparable to conventional subcutaneously injected prandial insulins but with improved control of early postprandial BG. Furthermore, TI has been associated with less weight gain and a lower incidence of hypoglycemia, which may enhance patient satisfaction and acceptability of insulin therapy. This review discusses the clinical properties of TI and proposes strategies for optimal use.
PfütznerAMannAESteinerSS. Technosphere/Insulin–a new approach for effective delivery of human insulin via the pulmonary route. Diabetes Technol Ther.2002;4 (5): 589–94.
11.
PfütznerAForstT. Pulmonary insulin delivery by means of the Technosphere drug carrier mechanism. Expert Opin Drug Deliv.2005;2 (6): 1097–106.
12.
RaveKPotockaEHeinemannLHeiseTBossAHMarinoMCostelloDChenR. Pharmacokinetics and linear exposure of AFRESA compared with the subcutaneous injection of regular human insulin. Diabetes Obes Metab.2009;11 (7): 715–20.
BossARaveKCheathamWHeiseT. Inhaled Technosphere/insulin: Glucose elimination at the right time? Poster presented at: 65th Annual Scientific Sessions of the American Diabetes Association, June 10–14, 2005, San Diego, CA.
15.
CassidyJPBaughmanRASchwartzSLHaworthPCBossAHRichardsonPC. AFRESA (Technosphere insulin) dosage strengths are interchangeable. Poster presented at: 69th American Diabetes Association Scientific Sessions, June 5–9, 2009, New Orleans, LA.
16.
PotockaEHovorkaRBaughmanRKleinODellwegSUmplebyMHaworthPMillsRBossAHRichardsonPC. Characterization of metabolism parameters following Technosphere insulin and insulin lispro. Diabetes.2010;59Suppl 1: A413.
17.
RosenstockJLorberDLGnudiLHowardCPBilheimerDWChangPCPetrucciREBossAHRichardsonPC. Prandial inhaled insulin plus basal insulin glargine versus twice daily biaspart insulin for type 2 diabetes: A multicentre randomised trial. Lancet.2010;375 (9733): 2244–53.
18.
PotockaEHovorkaRBaughmanRAUmplebyMDiazMLChenRBossAHRichardsonPC. AFRESA™ suppresses endogenous glucose production earlier than a rapid-acting analog (lispro) and inhaled Exubera. Diabetes.2009;58Suppl 1: A61.
19.
BergenstalRMKapsnerPLRendellMSBossAHHowardCPChangPC. Comparative efficacy and safety of AFRESA and rapid-acting analog both given with glargine in subjects with T1DM in a 52-week study. Presented at: 69th American Diabetes Association Scientific Sessions, June 5–9, 2009, New Orleans, LA.
20.
GargSKMcGillJBRosenstockJHirschIBPetrucciRChangPC. Technosphere insulin vs insulin lispro in patients with type 1 diabetes using multiple daily injections. Presented at: 71st Annual Scientific Sessions of the American Diabetes Association, June 24–28, 2011, San Diego, CA.
21.
RaskinPPhillipsMDRossiterABossAHRichardsonPC. A1C and hypoglycemia in patients with type 2 diabetes mellitus incorporating prandial inhaled Technosphere insulin into their usual antihyperglycemic regimen vs continuing their usual antihyperglycemic regimen. Presented at: 70th Scientific Sessions of the American Diabetes Association, June 25–29, 2010, Orlando, FL.
22.
DeVriesJH. Mealtime inhaled insulin lowers fasting glucose: A look at possible explanations. Diabetologia.2005;48 (12): 2682–3.
23.
BilheimerDRenHaoBossAH. Analysis of cardiovascular adverse events in patients with type 1 or type 2 diabetes enrolled in selected therapeutic trials in the phase 2/3 Technosphere insulin development program. Presented at: 71st Annual Scientific Sessions of the American Diabetes Association, June 24–28, 2011, San Diego, CA.
24.
RaskinPHellerSHonkaMChangPCBossAHRichardsonPCAminN. Pulmonary function over 2 years in diabetic patients treated with prandial inhaled Technosphere Insulin or usual antidiabetes treatment: A randomized trial. Diabetes Obes Metab.2012;14 (2): 163–73.
GreeneSNikulaKReynoldsJPoulinDMcInallyKTownsonDRichardsonP. Long-term pulmonary safety assessment of Afrezza™ in rats and dogs. Toxicologist.2011;120Suppl 2: 175.
27.
KorytkowskiMNiskanenLAsakuraT. FlexPen: Addressing issues of confidence and convenience in insulin delivery. Clin Ther.2005;27Suppl B: S89–100
28.
KorytkowskiM. When oral agents fail: Practical barriers to starting insulin. Int J Obes Relat Metab Disord.2002;26Suppl 3: S18–24
29.
HuntLMValenzuelaMAPughJA. NIDDM patients' fears and hopes about insulin therapy. The basis of patient reluctance. Diabetes Care.1997;20 (3): 292–8.
30.
PeyrotMRubinRR. Patient-reported outcomes in adults with type 2 diabetes using mealtime inhaled technosphere insulin and basal insulin versus premixed insulin. Diabetes Technol Ther.2011;13 (12): 1201–6.
31.
PeyrotMRubinRR. Patient reported outcomes in adults with type 2 diabetes using mealtime AFRESA (inhaled Technosphere insulin) or metformin + secretagogue or both. Presented at: 69th American Diabetes Association Scientific Sessions, June 5, 2009, New Orleans, LA.
32.
CoatesPAIsmailISLuzioSDGriffithsIOllertonRLVølundAOwensDR. Intranasal insulin: The effects of three dose regimens on postprandial glycaemic profiles in type II diabetic subjects. Diabet Med.1995;12 (3): 235–9.
33.
LeeJJDassauEZisserHJovanovicLDoyleFJIII. Semi-automated artificial pancreas using prandial inhaled insulin and zone — Model predictive control. Presented at: 12th Annual UC Systemwide Bioengineering Symposium, June 13–15, 2011, Santa Barbara, CA.
34.
GargSKellyWFresonBPetrucciRRitchieP. Treat-to-target Technosphere insulin in patients with type 1 diabetes. Presented at: 71st Annual Scientific Sessions of the American Diabetes Association, June 24–28, 2011, San Diego, CA.
